The stem cell secretome is the mixture of substances that stem cells release, including proteins, lipids, RNA and extracellular vesicles (EVs). These substances can carry signals between cells. A cell-free secretome preparation contains the released material, not living stem cells, and exosomes are only one possible part of that mixture.PMC6562906
Most research discussed here concerns mesenchymal stem/stromal cells (MSCs) from bone marrow, fat or umbilical cord. It does not cover induced pluripotent or embryonic stem cell secretomes. Two human studies below enrolled 9 and 30 participants; those small studies do not establish that secretome treatments work across diseases.

Is secretome therapy stem cell therapy?
Not in the sense of transplanting living cells. A cell-free secretome preparation cannot divide, engraft or turn into cartilage, nerve or heart muscle. Researchers instead study whether its released factors influence the patient’s existing cells. That is a proposed mechanism, not proof of tissue regeneration in patients.PMC6562906PMC5618501
There is no single, fixed secretome formula. Cell source, donor, culture medium, oxygen level, collection time and passage number (how often cells are transferred to fresh culture vessels) can change its composition and yield.PMC10454619 Particle count or total protein concentration alone does not establish a therapeutic dose or predict benefit.PMC10850029
What is inside the secretome?
Researchers often study the released material in MSC-conditioned medium (MSC-CM), the liquid in which the cells were cultured. Reported components include the following.
| Component | Examples | What studies suggest |
|---|---|---|
| Growth factors and cytokines | VEGF, HGF, FGF-2, TGF-β, IL-6, IL-10, IL-1RA | Roles include blood-vessel signaling and modulation of inflammation. MSC-conditioned medium helped endothelial cells form tube-like structures in laboratory studies.PMC6562906PMC5618501 |
| Chemokines | CXCL12/SDF-1, CCL2 | CXCL12 and CCL2 act as chemical beacons for immune cells; MSC-CM contains both.PMC6562906PMC5618501 |
| Immune-modulating factors | PGE2, TSG-6 | These factors participate in regulation of inflammatory and immune responses in experimental systems.PMC6562906PMC5618501 |
| Extracellular vesicles | small EVs often called exosomes; proteins, lipids, mRNA, miRNA | Carry mRNA, miRNA and proteins; can transfer them to recipient cells.PMC6562906PMC10850029 |
| Matrix proteins and enzymes | collagen, matrix metalloproteinases (MMPs) | Collagen provides a scaffold; MMPs degrade matrix proteins.PMC6562906 |
These are examples reported in research, not a guaranteed ingredient list for a commercial vial. Most proposed effects come from cell or animal studies, not proof that an injection helps a particular human disease.PMC6562906PMC5618501
How is it made?
Published protocols differ in cell source, passage, medium, conditioning time and purification; a 2023 review found no consensus on the optimal combination.PMC10454619
- Choose a cell source and donor. Bone marrow, adipose tissue, umbilical cord and other tissues give different starting cells. Donor characteristics such as age, sex, metabolic state and disease may also change the secretome.PMC10454619
- Expand the cells over several passages to the target number; passage number itself changes the secretome.PMC10454619
- Wash the cells and switch to a collection medium. Some processes use serum-free or chemically defined medium; others use serum-containing medium.
- Condition the medium for a pre-specified period; the 2023 review notes no consensus on the optimal duration.PMC10454619
- Remove cells and large debris by centrifugation and filtration.
- Concentrate or separate fractions. Ultracentrifugation can co-isolate non-vesicular material; size-exclusion chromatography separates by size; ultrafiltration can concentrate material but does not by itself establish EV purity.PMC10850029
- Define batch-release tests for identity, sterility, endotoxin, composition and biological activity. Storage and any freezing or freeze-drying process need product-specific validation; this is a quality-control requirement, not a guarantee that every marketed product meets it.PMC10454619
Serum is a particular challenge: fetal bovine serum contains its own EVs and proteins, and it can introduce animal-derived material into the final product. MISEV2023, the current consensus guidance for EV research, notes that serum and platelet lysate are rich in EVs and other undefined components, and that removing them completely is difficult to verify.PMC10850029 The manufacturing review reaches a similar conclusion and recommends serum-free or chemically defined media where possible.PMC10454619
This is a contamination and characterization concern, not evidence that every serum-containing preparation causes harm.PMC10454619PMC10850029
Secretome, exosomes and conditioned medium
They are not interchangeable. The secretome is the released material; conditioned medium is the liquid containing it; exosomes are one subtype of vesicle within it.
| Term | What it usually means | What to keep in mind |
|---|---|---|
| Stem cell secretome | The full set of factors and vesicles released by stem cells | A broad biological description, not a product specification |
| Conditioned medium | The liquid collected after cells have been cultured in it | Contains the secretome plus medium components, and possibly serum |
| Exosomes | A subtype of small EVs that form inside the cell’s endosomal system | The term is often used loosely for any small EV; origin is rarely proven |
| Extracellular vesicles (EVs) | Membrane-bound particles released by cells | An umbrella term; includes small and large EVs |
MISEV2023 recommends using “EV” unless the vesicle’s origin is demonstrated. “Exosome” describes formation through the cell’s endosomal system, not simply a size range. Size alone cannot establish that identity.PMC10850029
An “exosome” label alone is therefore insufficient: ask whether the preparation is whole conditioned medium, an EV-enriched fraction or a specifically characterized vesicle product.PMC10850029
Why study a cell-free treatment?
Researchers hope to use MSC-released signals without needing living cells to remain viable during storage and administration. Cell-free preparations may offer handling advantages, but their stability, biological activity and storage conditions still require testing.PMC5618501PMC10454619 Removing cells does not remove all immune risks: EVs may carry molecules that interact with the immune system.PMC6562906
Does it work in people?
Small human studies report signals of benefit, but the studies discussed here do not establish broadly applicable efficacy or long-term safety. Evidence concerns the particular preparation, disease and route tested, not “secretome therapy” as a whole.
Laboratory and animal findings
In cell culture, MSC-conditioned medium (MSC-CM) has reduced T-cell proliferation and supported endothelial tube formation. These are laboratory measurements of cell behavior, not patient outcomes.PMC6562906PMC5618501
Animal lung-injury studies also suggest repair-related effects involving keratinocyte growth factor (KGF). Such findings help generate hypotheses; they do not establish that an infusion repairs human lungs or other organs.PMC6562906
What do human trials show?
Two examples show why product details matter. Neither of these two studies used a placebo or blinded assessment.
| Study | Product and route | Participants and design | Main finding | Limits |
|---|---|---|---|---|
| Phase 1b corneal trial, 2026 | Allogeneic bone marrow MSC secretome eye drops for persistent corneal epithelial disease associated with neurotrophic keratitis and/or limbal stem cell deficiency | 9 participants; single-center, uncontrolled, open-label dose escalation; 28-day treatment; safety assessed up to 90 days | No dose-limiting toxicity at 2 or 4 times daily; 2 of 3 participants at 6 times daily developed reversible dose-limiting toxicity | Safety and maximum tolerated dose were primary outcomes; not a controlled efficacy test.42667833 |
| Knee osteoarthritis trial, 2023 | Umbilical cord MSC secretome, intra-articular injection; Indonesia | 30 participants; open-label comparison with hyaluronic acid; VAS pain scores, WOMAC symptoms/function and biomarkers; 5-week interval | Authors reported better clinical scores and no side effects in the secretome group | Small, unblinded and short; does not establish durable benefit, cartilage repair or uncommon-harm rates.38002750 |
In the corneal study, dose-limiting events included a new epithelial defect and increased corneal staining with a transient reduction in best-corrected visual acuity. “Reversible” does not mean that higher-frequency dosing was harmless.42667833
The knee study also reported a lower MMP-3 ratio and higher TGF-β1 relative to the hyaluronic acid group. Biomarker changes are not proof of regenerated cartilage. Lack of blinding, a small sample and short follow-up limit confidence in the reported symptom benefit.38002750
Placebo-controlled trials also exist; not all secretome research is unblinded. A phase I/II severe COVID-19 study used menstrual blood stromal cell secretome intravenously: 30 patients entered, one discontinued and 29 were analyzed, with 28-day monitoring.35255966 A lupus trial randomized 29 women with moderate disease activity to weekly intramuscular umbilical cord MSC secretome or saline placebo, with assessment through Day 43.40352183 These small studies used different preparations and outcomes; neither validates unrelated eye drops, joint injections or anti-aging offers.
How to judge a treatment claim
A persuasive evidence package would define the preparation and its biological activity, use an appropriate comparator and patient-relevant outcomes, and include enough participants and follow-up to assess benefit and harm. Independent replication would strengthen confidence. A pain score, laboratory biomarker and safety endpoint answer different questions.
A trial registration is not a result; it only shows that a study exists. Publication in a peer-reviewed journal does not mean the design was adequate; check the sample size, control group and follow-up.
Is it safe?
Safety depends on the preparation, dose and administration route. The corneal study detected dose-limiting toxicity, while the knee study reported no side effects during its short observation period.4266783338002750 These are not contradictory findings, because they concern different products and patients.
The COVID-19 investigators reported no infusion-attributed adverse reactions, but serious events and deaths occurred during severe illness and were attributed by the authors to disease progression. That is not the same as saying no adverse events occurred.35255966 The lupus investigators reported no severe adverse events through Day 43.40352183 Studies this small cannot reliably exclude uncommon harms.
- Infection and contamination. A cell culture fluid is a good medium for microbes if it is not properly processed and tested.
- Immune reactions. Donor proteins, EVs or leftover serum components can set off a reaction. Cell-free does not mean immune-silent.PMC6562906PMC10454619
- Batch variability. Changes in production can alter composition and activity; a potency test assesses biological activity but does not by itself ensure that batches are identical.PMC10454619
- Unwanted biological effects. Growth factors such as VEGF are not tissue-specific; the long-term effects of repeated exposure are unknown.PMC6562906PMC5618501
- Procedure-related risks. The route matters. An eye drop, a joint injection and an intravenous infusion carry different risks.
The four human trials discussed here do not provide follow-up beyond 90 days. They cannot establish the long-term safety of repeated treatment.
Is it approved in the US or Japan?
Exosome products intended to treat disease generally require FDA approval; the FDA’s 2020 alert stated that none was approved at the time and warned that some marketed regenerative products have not been shown to be safe or effective.Consumer alert regenerative medicine products including stem cells and exosomes
The FDA’s list of approved cellular and gene therapy products, current as of September 17, 2026, contains no secretome, exosome or conditioned-medium product.Approved cellular and gene therapy products Ryoncil, one FDA-approved MSC product, is different: it is a cell-based product approved for steroid-refractory acute graft-versus-host disease in children aged 2 months and older.Ryoncil Its approval does not cover a cell-free secretome or any other MSC product.
The Act on the Safety of Regenerative Medicine (ASRM) covers the provision of regenerative medicine in medical practice and research, including advance filing and committee review. The Pharmaceuticals and Medical Devices Act (PMD Act) covers the commercialization of regenerative medical products. PMDA’s framework describes these products as processed living human or animal cells intended to repair, treat or prevent disease, or as gene therapy products.0003
PMDA’s approved regenerative medical product list, covering April 2015 through July 2026, contains no product identified as secretome, exosome or conditioned medium. However, this is one approval category, not a search of every Japanese medicine; absence from it alone cannot establish a nationwide absence of drug approvals.000283257.pdf
More directly relevant, the Ministry of Health, Labour and Welfare (MHLW) stated in a July 31, 2024 notice that no medicines using these stem-cell culture supernatants or related secretions had demonstrated efficacy and safety and obtained marketing approval at that time, including overseas. It urged clinicians to pay particular attention to safety. This is a dated warning, not a new 2026 approval determination.001281987.pdf
The EV guidance presented on MHLW’s website in June 2024 describes physician-prepared EV administration as outside the ASRM’s scope at that time. Do not assume that a clinic’s cell-therapy filing covers a cell-free product. Check the exact product and procedure when assessing registration and product approval; neither a clinic license nor a filing for a different treatment establishes secretome efficacy.001263950.pdf
None of this means that every private clinic is breaking the law. Medical practice and product approval are different legal categories. A clinic may be licensed to practice, but that license is not a product approval. Whether a specific service is lawful depends on the jurisdiction and the claims being made.
| Category | What it means | Secretome example |
|---|---|---|
| Approved medicine | A regulator authorizes a specified product for a defined indication under its approval pathway | Request the product’s authorization and approved indication, not a clinic registration number |
| Clinical trial | Research under a study protocol; registry entry alone does not prove efficacy or adequate oversight | The corneal phase 1b study is early safety research, not an approved routine treatment |
| Private clinic service | Care offered under medical practice rules; this is not the same as product approval | “Exosome” or “stem cell supernatant” sold self-pay |
The regulatory sources above were rechecked on October 27, 2026. Their stated publication dates and category limits still apply. Rules outside the US and Japan were not assessed; legality and proven clinical benefit are separate questions.
What to ask a clinic
| Question | Why it matters |
|---|---|
| What exactly is in the product? | “Secretome” is a category, not a drug name. Ask whether it is conditioned medium, a mixed EV preparation, or a purified fraction. |
| Which cells and donor? | Bone marrow, fat, umbilical cord and donor characteristics can change the mix. |
| How is each batch characterized? | Ask for particle count, protein content, marker testing, sterility, endotoxin, residual serum, and a potency assay. |
| What is the regulatory status? | Is it an approved medicine, a registered clinical trial, or a self-pay service? Get the registration number and the indication. |
| What human trial supports this use? | Ask for the diagnosis, number of participants, control group, endpoint, follow-up, and adverse events. |
| What are the alternatives? | Compare with standard treatment and with registered trials. |
| Who manages complications? | A clear follow-up plan matters more than a glossy brochure. |
Applying the evidence to an offer
Suppose a clinic cites the nine-person eye-drop study to support an intravenous anti-aging infusion. Compare three details: the study treated corneal disease, used topical drops and primarily tested safety and maximum tolerated dose. None matches the proposed infusion or proves an anti-aging benefit. This is an illustrative reading exercise, not a patient case or personal treatment experience.42667833
For a specific offer, ask for the exact preparation, batch-release results, authorization if approval is claimed, and a study matching the disease and route. A missing document is an evidence gap; a trial registration number alone does not fill it.
Unsure what a secretome offer actually includes?
Contact our team with the product name and your questions about the proposed care. Discuss clinical suitability and alternatives with your treating specialist.
Bottom line
The stem cell secretome is released biological material, not a stem cell transplant and not a synonym for exosomes. The 9-person corneal study and 30-person knee study illustrate early, product-specific research, not proof of broad regenerative benefit.4266783338002750
The FDA list dated September 17, 2026 and PMDA regenerative-product list through July 2026 contain no identified secretome product in those categories. Check any claimed approval against the exact product, indication and regulator rather than a clinic’s general status.Approved cellular and gene therapy products000283257.pdf
Discuss established options and suitable clinical trials with your specialist before paying for an experimental intervention. This article explains published research and regulatory documents; it does not report personal treatment experience and is not a substitute for individual medical advice.
References
Sources 1–4 were accessed on October 24, 2026. Sources 5–15 were rechecked or added on October 27, 2026; the trial abstracts were also retrieved through Europe PMC’s public research index.
- Harrell CR, Fellabaum C, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Molecular mechanisms responsible for therapeutic potential of mesenchymal stem cell-derived secretome. Cells. 2019;8(5):467. doi:10.3390/cells8050467. https://pmc.ncbi.nlm.nih.gov/articles/PMC6562906/
- Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. International Journal of Molecular Sciences. 2017;18(9):1852. doi:10.3390/ijms18091852. https://pmc.ncbi.nlm.nih.gov/articles/PMC5618501/
- Chouaib B, Haack-Sørensen M, Chaubron F, Cuisinier F, Collart-Dutilleul PY. Towards the standardization of mesenchymal stem cell secretome-derived product manufacturing for tissue regeneration. International Journal of Molecular Sciences. 2023;24(16):12594. doi:10.3390/ijms241612594. https://pmc.ncbi.nlm.nih.gov/articles/PMC10454619/
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. Journal of Extracellular Vesicles. 2024;13(2):e12404. doi:10.1002/jev2.12404. https://pmc.ncbi.nlm.nih.gov/articles/PMC10850029/
- Abedi F, Kwon JE, Araujo I, et al. Safety and tolerability of topical mesenchymal stromal cell secretome in persistent corneal epithelial disease—a phase 1b clinical trial. Cytotherapy. 2026;28:102958. doi:10.1016/j.jcyt.2026.102958. https://pubmed.ncbi.nlm.nih.gov/42667833/
- Partan RU, Putra KM, Kusuma NF, et al. Umbilical cord mesenchymal stem cell secretome improves clinical outcomes and changes biomarkers in knee osteoarthritis. Journal of Clinical Medicine. 2023;12(22):7138. doi:10.3390/jcm12227138. https://pubmed.ncbi.nlm.nih.gov/38002750/
- Fathi-Kazerooni M, Fattah-Ghazi S, Darzi M, et al. Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II. Stem Cell Research & Therapy. 2022;13:96. doi:10.1186/s13287-022-02771-w. https://pubmed.ncbi.nlm.nih.gov/35255966/
- Nurudhin A, Werdiningsih Y, Sunarso I, et al. Umbilical cord mesenchymal stem cell-derived secretome as a potential treatment for systemic lupus erythematosus: a double-blind randomized controlled trial. Narra J. 2025;5:e1799. doi:10.52225/narra.v5i1.1799. https://pubmed.ncbi.nlm.nih.gov/40352183/
- U.S. Food and Drug Administration. Consumer alert on regenerative medicine products including stem cells and exosomes. July 22, 2020; content current as of April 9, 2024. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes
- U.S. Food and Drug Administration. Approved cellular and gene therapy products. Content current as of September 17, 2026. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
- U.S. Food and Drug Administration. RYONCIL (remestemcel-L-rknd). Content current as of January 17, 2025. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/ryoncil
- Pharmaceuticals and Medical Devices Agency. Regenerative medical products: regulatory framework. https://www.pmda.go.jp/english/review-services/reviews/0003.html
- Pharmaceuticals and Medical Devices Agency. List of approved regenerative medical products, April 2015 to July 2026. https://www.pmda.go.jp/files/000283257.pdf
- Ministry of Health, Labour and Welfare. Notice on medical care using stem cell culture supernatants and exosomes, July 31, 2024 (Japanese). https://www.mhlw.go.jp/content/001281987.pdf
- Japanese Society for Regenerative Medicine. Guidance on clinical application of extracellular vesicles; presentation hosted by MHLW, June 14, 2024 (Japanese). https://www.mhlw.go.jp/content/10808000/001263950.pdf




